Your browser doesn't support javascript.
loading
Engineering Microorganisms for Cancer Immunotherapy.
Liu, Dingkang; Yu, Lichao; Rong, Haibo; Liu, Lubin; Yin, Jun.
Afiliación
  • Liu D; Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, No. 639 Longmian Avenue, Nanjing, 211198, China.
  • Yu L; Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, No. 639 Longmian Avenue, Nanjing, 211198, China.
  • Rong H; Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Nanjing Medical University Affiliated Cancer Hospital, Nanjing, 210009, China.
  • Liu L; Department of Obstetrics and Gynecology, Women and Children's Hospital of Chongqing Medical University, No. 120 Longshan Road, Chongqing, 401147, China.
  • Yin J; Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, No. 639 Longmian Avenue, Nanjing, 211198, China.
Adv Healthc Mater ; 13(18): e2304649, 2024 Jul.
Article en En | MEDLINE | ID: mdl-38598792
ABSTRACT
Cancer immunotherapy presents a promising approach to fight against cancer by utilizing the immune system. Recently, engineered microorganisms have emerged as a potential strategy in cancer immunotherapy. These microorganisms, including bacteria and viruses, can be designed and modified using synthetic biology and genetic engineering techniques to target cancer cells and modulate the immune system. This review delves into various microorganism-based therapies for cancer immunotherapy, encompassing strategies for enhancing efficacy while ensuring safety and ethical considerations. The development of these therapies holds immense potential in offering innovative personalized treatments for cancer.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Ingeniería Genética / Inmunoterapia / Neoplasias Límite: Animals / Humans Idioma: En Revista: Adv Healthc Mater Año: 2024 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Ingeniería Genética / Inmunoterapia / Neoplasias Límite: Animals / Humans Idioma: En Revista: Adv Healthc Mater Año: 2024 Tipo del documento: Article País de afiliación: China